Herpes Zoster Vaccine in Organ Transplant Recipients
common.study.values.description
“Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients”
The investigators plan to study the immunogenicity of the vaccine in VZV-seronegative solid organ transplant recipients. VZV-seronegative patients will be enrolled after organ transplantation. The investigators hypothesize that the recombinant subunit Herpes zoster vaccine is able to induce cellular immunogenicity after transplantation in VZV-seronegative patients.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
Biological - recombinant subunit Herpes zoster vaccine
Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
participant.views.study.view.additional
participant.views.study.view.scientific-title
Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine in VZV-seronegative Solid Organ Transplant Recipients
common.study.values.clinical-trial-id
NCT03685682
participant.views.study.view.id
axk29e
